CN1126492A - 腮腺炎病毒的重组抗原及其在疫苗中的用途 - Google Patents
腮腺炎病毒的重组抗原及其在疫苗中的用途 Download PDFInfo
- Publication number
- CN1126492A CN1126492A CN94192620.6A CN94192620A CN1126492A CN 1126492 A CN1126492 A CN 1126492A CN 94192620 A CN94192620 A CN 94192620A CN 1126492 A CN1126492 A CN 1126492A
- Authority
- CN
- China
- Prior art keywords
- protein
- carrier
- paper
- called
- zone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000711386 Mumps virus Species 0.000 title claims abstract description 29
- 239000000427 antigen Substances 0.000 title claims abstract description 5
- 102000036639 antigens Human genes 0.000 title claims abstract description 5
- 108091007433 antigens Proteins 0.000 title claims abstract description 5
- 229960005486 vaccine Drugs 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 57
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 57
- 101710133291 Hemagglutinin-neuraminidase Proteins 0.000 claims abstract description 44
- 210000004027 cell Anatomy 0.000 claims abstract description 30
- 230000004927 fusion Effects 0.000 claims abstract description 24
- 108020004414 DNA Proteins 0.000 claims abstract description 15
- 108090001074 Nucleocapsid Proteins Proteins 0.000 claims abstract description 11
- 239000013598 vector Substances 0.000 claims abstract description 10
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims abstract description 8
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 5
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 5
- 230000001580 bacterial effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 229940083538 smallpox vaccine Drugs 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000001890 transfection Methods 0.000 claims description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 7
- 102000005396 glutamine synthetase Human genes 0.000 claims description 7
- 108020002326 glutamine synthetase Proteins 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 238000012546 transfer Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000010561 standard procedure Methods 0.000 claims description 3
- 102000037865 fusion proteins Human genes 0.000 abstract description 8
- 108020001507 fusion proteins Proteins 0.000 abstract description 8
- 239000012528 membrane Substances 0.000 abstract 2
- 241000700618 Vaccinia virus Species 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 description 53
- 239000012634 fragment Substances 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 108020005038 Terminator Codon Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 230000029087 digestion Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 241000699800 Cricetinae Species 0.000 description 6
- 238000006062 fragmentation reaction Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- 241000699802 Cricetulus griseus Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010046865 Vaccinia virus infection Diseases 0.000 description 5
- 238000005336 cracking Methods 0.000 description 5
- 238000013467 fragmentation Methods 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 210000001672 ovary Anatomy 0.000 description 5
- 208000007089 vaccinia Diseases 0.000 description 5
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 4
- 108091035707 Consensus sequence Proteins 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008521 reorganization Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 101710153593 Albumin A Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010034038 Parotitis Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002303 anti-venom Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000011553 hamster model Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000012133 immunoprecipitate Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100245267 Caenorhabditis elegans pas-1 gene Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101000914035 Homo sapiens Pre-mRNA-splicing regulator WTAP Proteins 0.000 description 1
- 101100170937 Mus musculus Dnmt1 gene Proteins 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- 102100026431 Pre-mRNA-splicing regulator WTAP Human genes 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101150013664 Pwwp3a gene Proteins 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960003311 ampicillin trihydrate Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000024835 cytogamy Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000030253 developmental and epileptic encephalopathy 14 Diseases 0.000 description 1
- 208000021651 developmental and epileptic encephalopathy, 14 Diseases 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- -1 especially F Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000009083 hemolysis by symbiont of host erythrocytes Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 125000005555 sulfoximide group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000008478 viral entry into host cell Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9308963.9 | 1993-04-30 | ||
| GB939308963A GB9308963D0 (en) | 1993-04-30 | 1993-04-30 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1126492A true CN1126492A (zh) | 1996-07-10 |
Family
ID=10734747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN94192620.6A Pending CN1126492A (zh) | 1993-04-30 | 1994-04-26 | 腮腺炎病毒的重组抗原及其在疫苗中的用途 |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0695358A1 (fr) |
| JP (1) | JPH08512199A (fr) |
| KR (1) | KR960702000A (fr) |
| CN (1) | CN1126492A (fr) |
| AU (1) | AU6964894A (fr) |
| CA (1) | CA2161645A1 (fr) |
| GB (1) | GB9308963D0 (fr) |
| WO (1) | WO1994025600A1 (fr) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843507B (zh) * | 2006-02-14 | 2010-04-21 | 中国医学科学院医学生物学研究所 | 一种人用腮腺炎病毒组份疫苗及其制备方法和应用 |
| CN106290862A (zh) * | 2016-08-05 | 2017-01-04 | 北京市华信行生物科技有限公司 | 腮腺炎病毒hn抗原及其在检测抗腮腺炎病毒抗体中的用途 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100064A (en) * | 1984-04-06 | 2000-08-08 | Chiron Corporation | Secreted viral proteins useful for vaccines and diagnostics |
| EP0966534B1 (fr) * | 1997-03-11 | 2005-02-02 | Mayo Foundation for Medical Education and Research | Compositions et methodes d'elimination de cellules indesirables |
| EP0988052A2 (fr) * | 1997-05-23 | 2000-03-29 | SCHWEIZ. SERUM- & IMPFINSTITUT BERN | Vaccin comprenant de l'adn a enveloppe du virus de la grippe |
| AU5980899A (en) * | 1998-09-25 | 2000-04-17 | Smithkline Beecham Biologicals (Sa) | Novel compounds |
| IL293666A (en) * | 2019-12-11 | 2022-08-01 | Us Health | Mumps and measles virus immunogens and their use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3740189A (en) * | 1988-05-24 | 1989-12-12 | Board Of Regents, The University Of Texas System | Mumps virus hemagglutinin-neuraminidase |
-
1993
- 1993-04-30 GB GB939308963A patent/GB9308963D0/en active Pending
-
1994
- 1994-04-26 CA CA002161645A patent/CA2161645A1/fr not_active Abandoned
- 1994-04-26 KR KR1019950704819A patent/KR960702000A/ko not_active Application Discontinuation
- 1994-04-26 JP JP6523863A patent/JPH08512199A/ja active Pending
- 1994-04-26 CN CN94192620.6A patent/CN1126492A/zh active Pending
- 1994-04-26 WO PCT/EP1994/001297 patent/WO1994025600A1/fr not_active Application Discontinuation
- 1994-04-26 EP EP94915539A patent/EP0695358A1/fr not_active Withdrawn
- 1994-04-26 AU AU69648/94A patent/AU6964894A/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1843507B (zh) * | 2006-02-14 | 2010-04-21 | 中国医学科学院医学生物学研究所 | 一种人用腮腺炎病毒组份疫苗及其制备方法和应用 |
| CN106290862A (zh) * | 2016-08-05 | 2017-01-04 | 北京市华信行生物科技有限公司 | 腮腺炎病毒hn抗原及其在检测抗腮腺炎病毒抗体中的用途 |
| CN106290862B (zh) * | 2016-08-05 | 2017-10-31 | 北京市华信行生物科技有限公司 | 腮腺炎病毒hn抗原及其在检测抗腮腺炎病毒抗体中的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9308963D0 (en) | 1993-06-16 |
| AU6964894A (en) | 1994-11-21 |
| KR960702000A (ko) | 1996-03-28 |
| JPH08512199A (ja) | 1996-12-24 |
| EP0695358A1 (fr) | 1996-02-07 |
| CA2161645A1 (fr) | 1994-11-10 |
| WO1994025600A1 (fr) | 1994-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Taylor et al. | Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens | |
| JP3602844B2 (ja) | 遺伝子操作したワクチン菌株 | |
| JP4108742B2 (ja) | ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法 | |
| DK170948B1 (da) | Ikke naturligt forekommende pseudorabiesvirus, vaccine indeholdende dette virus samt fremgangsmåde til serologisk skelnen mellem inficerede og vaccinerede dyr | |
| JPH05103667A (ja) | シチメンチヨウの組換えヘルペスウイルスおよび該ウイルス由来の生菌ベクターワクチン | |
| CN104471064B (zh) | 副粘病毒及其用途 | |
| JP3939358B2 (ja) | 組替え豚痘ウイルス | |
| JPH05262667A (ja) | ウイルス抗原を用いるワクチン | |
| CN108586618A (zh) | 一种猪流行性腹泻亚单位疫苗的制备及应用 | |
| JP3824619B2 (ja) | 麻疹ウイルス組換え体ポックスウイルスワクチン | |
| RU2734118C2 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| CN1126492A (zh) | 腮腺炎病毒的重组抗原及其在疫苗中的用途 | |
| Shehata et al. | Development of a recombinant ELISA using yeast (Pichia pastoris)-expressed polypeptides for detection of antibodies against avian influenza A subtype H5 | |
| JP4691495B2 (ja) | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター | |
| Lehman et al. | Comparison of soluble and secreted forms of human parainfluenza virus type 3 glycoproteins expressed from mammalian and insect cells as subunit vaccines | |
| KR100265393B1 (ko) | 고양이 백혈병 바이러스 백신 | |
| JPH11507241A (ja) | 組換え鶏痘ウイルスおよびその使用 | |
| Cresta et al. | Biological properties of junin virus proteins: I. identification of the immunogenic glycoprotein | |
| AU2017275663B2 (en) | Modification of engineered influenza hemagglutinin polypeptides | |
| Thomsen et al. | Applications of insect cell gene expression in pharmaceutical research | |
| CN1117150C (zh) | 编码诊断相关的病毒衣壳抗原的eb病毒dna序列,通过聚合酶链反应产生的表达克隆和该重组抗原在诊断检测中的应用 | |
| Yoo et al. | Analysis of the S spike (peplomer) glycoprotein of bovine coronavirus synthesized in insect cells | |
| JP3990445B2 (ja) | バリセラ・ゾースターウィルス抗原 | |
| CN100999729A (zh) | 牛γ－干扰素在重组杆状病毒中的表达及抗病毒活性的测定 | |
| CA3112040A1 (fr) | Compositions et procedes de fabrication et d'utilisation de particules de type viral (vlp) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |